Enjoy complimentary customisation on priority with our Enterprise License!
The global allergy rhinitis drugs market size is estimated to grow by USD 3.17 billion at a CAGR of 3.92% between 2023 and 2028.
Technological advances in allergy rhinitis diagnostics have a favourable influence on the market growth. The significant challenge faced by the allergy rhinitis drugs market is the unclear pathogenesis and prognosis of various allergy indications. The unclear pathogenesis of these allergies leads to a poor diagnosis. Currently, blood tests, skin tests, and patch tests are being used to diagnose allergies. However, recent advances are helping to increase the number of patients being diagnosed in the early stages of allergy and, hence, making treatment more effective. For instance, Siemens Healthcare manufactured the IMMULITE 2000 XPi Immunoassay system, which is being used for the diagnosis of various medical conditions such as allergy, anaemia, autoimmune disorders, bone metabolism, diabetes, inflammation, various oncology indications, reproductive endocrinology, and thyroid. These advances are expected to lead to the identification of new allergens, which will lead to the development of better allergy rhinitis drugs, thus resulting in the growth of the global allergy rhinitis drugs market during the forecast period.
Technavio has segmented the market into Distribution Channel, Product and Geography
It also includes an in-depth analysis of drivers, trends, and challenges. Our report examines historical data from 2018-2022, besides analyzing the current market scenario.
To learn more about this report, Request Free Sample
The market share growth by the offline segment will be significant during the forecast period. The offline segment of allergy rhinitis drugs by retail pharmacies is a critical aspect of ensuring that patients have convenient access to the medications they need for managing allergy rhinitis conditions. Retail pharmacies, including chain pharmacies, independent pharmacies, and online pharmacies, play a significant role in the distribution process.
Get a glance at the market contribution of various segments Download PDF Sample
The offline segment was the largest and was valued at USD 9.96 billion in 2018. Offline segments maintain records of dispensed medications and patient information. This documentation is essential for record-keeping, patient history, and potential future interactions. In addition to that, retail pharmacies are often located in easily accessible locations, including urban and suburban areas. This accessibility ensures that patients can obtain their respiratory medications conveniently, even between healthcare provider visits. Moreover, pharmacists in retail settings offer consultations and recommendations for over-the-counter products to manage mild allergy rhinitis symptoms, enhancing the overall care experience for patients. Thus, factors such as the presence of pharmacist consultations and convenient access to medications will contribute to the growth of the offline segment, which will strengthen the global allergy rhinitis drugs market during the forecast period.
Antihistamines are a pharmaceutical class of drugs that act to treat histamine-mediated conditions. The antihistamines segment is expected to witness growth during the forecast period. The major growth driver is the increasing use of antihistamines as a first-line approach to prevent or relieve the symptoms of allergic rhinitis. Most of the guidelines, including the Allergy Rhinitis and its Impact on Asthma Guidelines published in 2016, recommend the use of oral and intranasal antihistamines as the first approach for managing the symptoms of allergy rhinitis. Moreover, intranasal antihistamines have the ability to deliver a higher concentration of medication to a specific area. Currently, Astelin and Pataday are the two FDA-approved intranasal antihistamine preparations for the treatment of allergy rhinitis. Therefore, the antihistamines segment is expected to grow in the global allergy rhinitis drugs market during the forecast period.
Intranasal corticosteroid drugs are the most preferred approach after antihistamines for the treatment of allergic rhinitis. One of the major factors that drive the growth of this segment is that intranasal corticosteroids are safe for long-term administration. Another factor is the patient convenience associated with the use of intranasal corticosteroids in the form of a spray, aerosol liquid, or aerosol powder. The market is expected to experience an accelerated growth momentum during the forecast period, owing to the increase in the demand for safe long-term treatments. Hence, more companies are investing in the manufacturing of intranasal corticosteroids. The development of novel corticosteroids is expected to fuel the growth of this segment in allergy rhinitis drugs during the forecast period.
For more insights about the market share of various regions Download PDF Sample now!
Asia is estimated to contribute 31% to the growth of the global market during the forecast period. Technavio’s analysts have elaborately explained the regional trends and drivers that will shape the market during the forecast period. Another region offering significant growth opportunities to companies is North America. The allergy rhinitis drugs market in North America is expected to grow tremendously during the forecast period. The growing prevalence of allergy rhinitis in the US and Canada is expected to accelerate the growth of the allergy rhinitis drug market in North America. In addition, the increasing awareness about the available treatment options among the patients and the presence of key players with extensive research and development capabilities help in maintaining the dominance of the market share in the region.
In addition, due to the increased awareness about allergy rhinitis drugs, the availability of technologically advanced allergy diagnostics instruments, and the developed healthcare infrastructure in Canada, the regional rhinitis drugs market is anticipated to grow. The increasing adoption of technologically advanced diagnostic equipment and the high prevalence of various types of allergic diseases, including allergic rhinitis, in the US will further enhance the growth of the allergy rhinitis drugs market in the region during the forecast period.
Companies are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market. The report also includes detailed analyses of the competitive landscape of the market and information about 20 market companies, including:
ALK Abello AS - This company offers allergy rhinitis drug such as Subcutaneous allergy immunotherapy (SCIT), Sublingual allergy immunotherapy (SLIT) drops, and SLIT tablets.
Qualitative and quantitative analysis of companies has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize companies as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize companies as dominant, leading, strong, tentative, and weak.
There are multiple factors influencing market growth. Our researchers analyzed the data with 2023 as the base year, along with the key drivers, trends, and challenges.
The increasing prevalence of allergy rhinitis is notably driving the market growth. The prevalence of allergic rhinitis has increased globally. For instance, according to an international study for asthma and allergies in childhood, in 2023, 14.6% in the 13 to 14-year age group and 8.5% in the 6 to 7-year age group, exhibit symptoms of rhinoconjunctivitis which is linked to allergic rhinitis. Seasonal allergic rhinitis is most common in the pediatric age group; chronic rhinitis is more prevalent in adults. Rhinitis is a common non-infectious rhinitis among the global population. Chronic allergy rhinitis patients will often have a family history of allergic rhinitis or a personal history of asthma.
In addition to genetic factors, lifestyle factors influence the prevalence of allergic rhinitis. The increase in the prevalence of allergy rhinitis is expected to increase the patient pool as well as the consumption of medicines. This increase in the worldwide incidence of allergy rhinitis is expected to drive the growth of the allergy rhinitis drugs market during the forecast period.
Increasing demand for over-the-counter medicines is an emerging trend shaping the market growth. There has been a rise in the demand for over-the-counter medicines for the treatment of allergic rhinitis. Patients with mild allergies do not require serious care, and they often self-medicate with over-the-counter drugs. Over-the-counter pills such as Claritin, Alavert, Astelin, and Astepro do not require a written prescription from a healthcare professional and can be directly purchased from pharmacies. Nasal washes can help remove mucus from the nose in mild allergy rhinitis. Nasal washes are easily available at pharmacies and can be purchased without a prescription. This promotes the use of over-the-counter drugs by individuals.
Moreover, these over-the-counter drugs have increased the practice of self-medication among individuals. Self-medication reduces the pressure of medical services. Therefore, patients are inclined toward over-the-counter drugs. Therefore, such factors foster the growth of the allergy rhinitis drugs market during the forecast period.
Increased use of complementary and alternative medicine is a significant challenge hindering market growth. The rising preference for complementary and alternative medicines (CAM) is a major challenge to the global allergy rhinitis therapeutics market. CAM therapies such as spirulina, butterbur, and phototherapy are extensively used in patients with allergic diseases worldwide. The popularity of using CAM for the treatment of allergic diseases is increasing in some European countries. Similarly, in Japan, according to a study, the proportions of patients treated with CAM were 7.1% of children and 19.2% of adults. Furthermore, 36.2% of adult patients reported that the treatments were effective. The major factors that fuel the adoption of CAM are its safety, convenience, and low price.
However, the most common alternative medicines for allergic rhinitis include traditional herbal medicines such as ginkgo extract, Urtica dioica, spirulina, and butterbur. Popular CAM therapies for allergy rhinitis include speleotherapy, homeopathy, and acupuncture. Therefore, the increased use of complementary and alternative medicine will negatively impact the growth of the allergy rhinitis drugs market during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Allergy Rhinitis Drugs Market Customer Landscape
The allergy rhinitis drugs market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2018 to 2028.
Allergy Rhinitis Drugs Market Scope |
|
Report Coverage |
Details |
Page number |
165 |
Base year |
2023 |
Historic period |
2018-2022 |
Forecast period |
2024-2028 |
Growth momentum & CAGR |
Accelerate at a CAGR of 3.92% |
Market Growth 2024-2028 |
USD 3.17 billion |
Market structure |
Fragmented |
YoY growth 2023-2024(%) |
3.54 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
Asia at 31% |
Key countries |
US, Germany, UK, France, and Japan |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
ALK Abello AS, Apotex Inc., Bayer AG, Cadila Pharmaceuticals Ltd., Catalent Inc., Dr Reddys Laboratories Ltd., Faes Farma SA, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., HAL Allergy BV, Haleon Plc, Hikma Pharmaceuticals Plc, KYORIN Holdings Inc., Merck and Co. Inc., Mitsubishi Chemical Group Corp., Novartis AG, Sanofi SA, Stallergenes Greer Ltd., Ube Corp., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and Market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Download Sample PDF at your Fingertips
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.